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Olfactory cleft inflammation present in seasonal allergic rhinitis & intranasal steroids 
Anita Sivam  
PURPOSE: Allergic rhinitis (AR) is commonly associated with olfactory loss, although the mechanism 
is not well studied. This study was designed to determine the effect of mometasone furoate (MF) on ol-
factory loss in seasonal AR (SAR) and to study its effect on inflammation in the olfactory region. 
METHODS: We performed a randomized, double-blind, placebo-controlled, parallel clinical trial in 17 
patients with SAR who had symptoms of impaired olfaction (Table 1). Subjects received MF or placebo 
for 2 weeks during their allergy season. Before and after treatment, we measured nasal peak inspiratory 
flow (NPIF), chemosensory quality of life, and objective olfactory function (the University of Pennsyl-
vania Smell Identification Test) (Figure 1). Additionally, nasal cytology samples were obtained from 
each visit, and a unilateral endoscopic biopsy specimen of the olfactory epithelium was obtained at the 
end of the study and scored for inflammation. 
RESULTS: Treatment with MF was associated with improved nasal symptoms (p < 0.015) (Figure 2a), 
NPIF (p < 0.04) (Figure 2b), reduced nasal inflammation (p < 0.05) (Figure 2c), and chemosensory-
specific quality of life (p < 0.03) (Figure 3). Histological analysis of the olfactory region reveals fewer 
eosinophils in the MF group when compared with placebo (p < 0.012). We found no improvement in 
objective olfactory function (p > 0.05). 
CONCLUSION: The use of MF in SAR is associated with reduced eosinophilic inflammation in the 
olfactory region and improved symptoms of AR. The presence of eosinophils in the olfactory area in 
SAR may indicate a direct, deleterious effect of inflammation on olfactory epithelium in this disease. In 
this study, we show that inflammation in SAR can affect the olfactory cleft, implicating a direct role for 
allergic inflammation in smell loss. Treatment with intranasal steroids is associated with decreased    
inflammation in the olfactory region in humans.  
Table 1. Characteristics of the Study Population. 
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Demographics Mometasone Furoate (n=8) 
Placebo 
 (n=9) 
  
Age (mean, range), y 40 (24-49) 38 (23-52) P=0.752 
Male n/% 2 (25) 5 (56) P=0.201 
Allergen Sensitivity       
Ragweed n/% 5 (63) 6 (66)   
Grass n/% 3 (37) 3 (33)   
Baseline Values       
Chemosensory QOL (mean±SEM) 24.3 ± 0.808 28.7 ± 1.92 P=0.078 
UPSIT Raw Score (median, range) 32 (27-37) 31 (17-37) P=0.459 
NPIF (median, range) 103 (90-147) 118 (67-191) P=0.224 
TNSS (median, range) 16.5 (13-26) 12 (6-26) P=0.440 
Eosinophils (median, range) 1.55 (0.5-4) 0.5 (0-1.5) P=0.028 
  
 
 
 
 
 
 
Figure 1. Study Design. Both treatments were daily nasal sprays given in the morning. NPIF indicates 
nasal peak inspiratory flow, QOL, quality of life, UPSIT, University of Pennsylvania Smell Identifica-
tion Test. 
 
 
 
Figure 2a. Change in total nasal symptom 
score from initial visit to two-week treatment 
with mometasone or placebo. Individual data 
points are depicted with the horizontal bars   
representing medians. Mometasone led to great-
er reduction of symptoms than placebo.  
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 Figure 2b. Nasal peak inspiratory flow (NPIF).    
Regarding changes from initial visit for all measure-
ments of NPIF, a negative number represents worsen-
ing, and a positive number represents improvement. 
Horizontal bars depict medians.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2c. Biopsy specimens were scored for in-
flammation by counting the number of eosinophils 
in three high power fields, with the average re-
ported. Subjects receiving MF showed significantly 
reduced numbers of eosinophils in the olfactory re-
gion compared to placebo. 
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Figure 3. Change in chemosensory quality of life (QOL). The overall quality-of-life score calculated 
from the Coping Style Questionnaire (CSQ) is shown. Mean ± SEM for the 2 groups at enrollment (V1) 
and after 2 weeks of treatment (V2). Increases on the y-axis indicate better quality of life.  
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